PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19118017-3	2009	Furthermore, when K5-PKCalpha mice were initiated with 7,12-dimethylbenz(a)anthracene (DMBA) and promoted with a low dose of TPA, 58% of K5-PKCalpha mice developed skin papillomas that progressed to carcinoma, whereas wild-type mice did not develop tumors.	7,12-dimethylbenz	55-72	protein kinase C, alpha	Mus musculus	21-29	
19118017-3	2009	Furthermore, when K5-PKCalpha mice were initiated with 7,12-dimethylbenz(a)anthracene (DMBA) and promoted with a low dose of TPA, 58% of K5-PKCalpha mice developed skin papillomas that progressed to carcinoma, whereas wild-type mice did not develop tumors.	7,12-dimethylbenz	55-72	protein kinase C, alpha	Mus musculus	140-148	
16103087-2	2005	PKCalpha-deficient mice exhibited increased susceptibility to tumor formation in two-stage skin carcinogenesis by single application of 7,12-dimethylbenz(a)anthracene (DMBA) for tumor initiation and repeated applications of 12-O-tetradecanoylphorbol-13-acetate (TPA) for tumor promotion.	7,12-dimethylbenz	136-153	protein kinase C, alpha	Mus musculus	0-8	
22843879-0	2012	PKCalpha suppresses 7,12-dimethylbenz[a]anthracene-induced skin tumor formation.	7,12-dimethylbenz	20-37	protein kinase C, alpha	Mus musculus	0-8